TITLE:
Quantitative EEG Changes in Patients with Parkinson’s Disease during Therapy with Rasagiline
AUTHORS:
Wilfried Dimpfel, Christian Oehlwein, Josef Anton Hoffmann, Thomas Müller
KEYWORDS:
Rasagiline, Selegiline, Quantitative EEG, CATEEM®, Parkinson’s Disease, Cognition
JOURNAL NAME:
Advances in Parkinson's Disease,
Vol.3 No.3,
August
28,
2014
ABSTRACT: It has been suggested that in patients with Parkinson’s disease (PD) metabolism of the MAO-B inhibitor selegiline to methamphetamine may contribute and/or exacerbate sleep problems, possibly leading to deficits of cognition. This open-label exploratory study included 30 PD patients currently being treated with selegiline (7.5 mg/day) and complaining of sleep disturbances. The aim of the study was to determine whether switching from selegiline to another MAO-B inhibitor without amphetamine-like metabolites, namely rasagiline, would improve sleep behaviour and cognitive function in PD patients. Pathologic aberrations as determined by comparison of the frequency pattern of patients to a database consisting of healthy subjects revealed an approximation of electric brain activity to normality. For verification of efficacy, a combination of questionnaires, quantitative source density EEG recording with CATEEMò and performance of two psychometric tasks (d2-test of attention and reading) during the EEG recording were done on the last day of selegiline treatment (7.5 mg/day) as well as 2 and 4 months later, during which the patients were treated with rasagiline (1 mg/day). In addition, performance of the mental tasks revealed a statistically significant (p